2,6-dichloro-2',3',5'-tri-O-acetyl-9-β-D-xylofuranosylpurine | 19806-62-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2,6-dichloro-2',3',5'-tri-O-acetyl-9-β-D-xylofuranosylpurine
• 英文别名: 9-(2,3,5-Tri-O-acetyl-β-D-xylofuranosyl)-2,6-dichloropurin；tri-O-acetyl-1-(2,6-dichloro-purin-9-yl)-β-D-1-deoxy-xylofuranose；[(2R,3S,4R,5R)-3,4-diacetyloxy-5-(2,6-dichloropurin-9-yl)oxolan-2-yl]methyl acetate
• CAS: 19806-62-3
• 化学式: C₁₆H₁₆Cl₂N₄O₇
• 分子量: 447.232
• InChiKey: PYXZXWLFAMZVPY-JDTTZNEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-2',3',5'-tri-O-acetyl-9-β-D-xylofuranosylpurine 在 palladium on activated charcoal 氢气 、 magnesium oxide 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以66%的产率得到2',3',5'-tri-O-acetyl-9-β-D-xylofuranosylpurine
  参考文献：
  名称：

  Gupta, P. K.; Bhakuni, D. S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1981, vol. 20, # 7, p. 534 - 537

  摘要：

  DOI：
• 作为产物：
  描述：

  chloromercuri 2,6-dichloropurine 、 2',3',5'-Tri-O-acetyl-9-β-D-xylofuranosyl bromide 以0.3 g的产率得到2,6-dichloro-2',3',5'-tri-O-acetyl-9-β-D-xylofuranosylpurine
  参考文献：
  名称：

  Gupta, P. K.; Bhakuni, D. S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1981, vol. 20, # 7, p. 534 - 537

  摘要：

  DOI：

文献信息

• MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：Pharmasset Limited

  公开号：EP1411954A2

  公开（公告）日：2004-04-28
• [EN] MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION<br/>[FR] NUCLEOSIDES MODIFIES POUR TRAITER DES INFECTIONS VIRALES ET UNE PROLIFERATION CELLULAIRE ANORMALE
  申请人：PHARMASSET LTD

  公开号：WO2002032920A2

  公开（公告）日：2002-04-25

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ('TR-PCR'). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.